BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 35378274)

  • 1. Advancement of cancer immunotherapy using nanoparticles-based nanomedicine.
    Gowd V; Ahmad A; Tarique M; Suhail M; Zughaibi TA; Tabrez S; Khan R
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):624-644. PubMed ID: 35378274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy.
    Boone CE; Wang L; Gautam A; Newton IG; Steinmetz NF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jan; 14(1):e1739. PubMed ID: 34296535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial prospects of nano-targeted chemoimmunotherapy.
    Da Silva CG; Rueda F; Löwik CW; Ossendorp F; Cruz LJ
    Biomaterials; 2016 Mar; 83():308-20. PubMed ID: 26796043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.
    Chakraborty K; Tripathi A; Mishra S; Mallick AM; Roy RS
    Biosci Rep; 2022 Jul; 42(7):. PubMed ID: 35638450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment.
    Yadav R; Das PP; Sharma S; Sengupta S; Kumar D; Sagar R
    Med Oncol; 2023 Nov; 40(12):347. PubMed ID: 37930458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.
    Li S; Bennett ZT; Sumer BD; Gao J
    Acc Chem Res; 2020 Nov; 53(11):2546-2557. PubMed ID: 33063517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.
    Grimaldi AM; Incoronato M; Salvatore M; Soricelli A
    Nanomedicine (Lond); 2017 Oct; 12(19):2349-2365. PubMed ID: 28868980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
    Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
    Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy.
    Peng S; Xiao F; Chen M; Gao H
    Adv Sci (Weinh); 2022 Jan; 9(1):e2103836. PubMed ID: 34796689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancement and Applications of Nanotherapy for Cancer Immune Microenvironment.
    He JJ; Li QQ; Zhao C; Zhou J; Wu J; Zhang HB; Zhao YQ; Zhang HH; Lei TY; Zhao XY; You Z; Song QB; Xu B
    Curr Med Sci; 2023 Aug; 43(4):631-646. PubMed ID: 37558863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
    Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted nanomedicine in cisplatin-based cancer therapeutics.
    Han Y; Wen P; Li J; Kataoka K
    J Control Release; 2022 May; 345():709-720. PubMed ID: 35367476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment.
    Gao S; Yang X; Xu J; Qiu N; Zhai G
    ACS Nano; 2021 Aug; 15(8):12567-12603. PubMed ID: 34339170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
    Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
    Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicines: Redefining traditional medicine.
    Lu W; Yao J; Zhu X; Qi Y
    Biomed Pharmacother; 2021 Feb; 134():111103. PubMed ID: 33338747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicine-based cancer immunotherapy: recent trends and future perspectives.
    Lakshmanan VK; Jindal S; Packirisamy G; Ojha S; Lian S; Kaushik A; Alzarooni AIMA; Metwally YAF; Thyagarajan SP; Do Jung Y; Chouaib S
    Cancer Gene Ther; 2021 Sep; 28(9):911-923. PubMed ID: 33558704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy and nanomedicine.
    Sheng WY; Huang L
    Pharm Res; 2011 Feb; 28(2):200-14. PubMed ID: 20821040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle delivery systems in cancer vaccines.
    Krishnamachari Y; Geary SM; Lemke CD; Salem AK
    Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.